Nicox (XPAR:ALCOX) ROCE % : -46.82% (As of Dec. 2023)

View and export this data going back to 1999. Start your Free Trial

What is Nicox ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Nicox's annualized ROCE % for the quarter that ended in Dec. 2023 was -46.82%.

Nicox ROCE % Historical Data

The historical data trend for Nicox's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nicox ROCE % Chart

Nicox Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

-17.95

-12.21

-38.88

-34.50

-34.27

Nicox Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
ROCE %	Get a 7-Day Free Trial															-56.76	-36.28	-31.36	-16.16	-46.82

Nicox ROCE % Calculation

Nicox's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-19.789	/	( ( (75.843 - 7.637)	+	(52.98 - 5.701) )	/ 2 )
	=	-19.789	/	( (68.206	+	47.279)	/ 2 )
	=	-19.789	/	57.7425
	=	-34.27 %

Nicox's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Jun. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Jun. 2023 )		(Q: Dec. 2023 )
	=	-28.168	/	( ( (82.283 - 9.247)	+	(52.98 - 5.701) )	/ 2 )
	=	-28.168	/	( ( 73.036	+	47.279 )	/ 2 )
	=	-28.168	/	60.1575
	=	-46.82 %

(1) Note: The EBIT data used here is two times the semi-annual (Dec. 2023) EBIT data.

Nicox (XPAR:ALCOX) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Nicox ROCE % Related Terms

Thank you for viewing the detailed overview of Nicox's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Nicox (XPAR:ALCOX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nicox SA (XPAR:ALCOX) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

NICXF:USA NXOA:Germany

Address

2405 route des Dolines, Drakkar 2 -Batiment D, Valbonne, Sophia Antipolis, FRA, 06560

Website

https://www.nicox.com

Nicox SA is an international company specializing in ophthalmology developing solutions aimed at maintaining vision and improving eye health. Nicox's program in clinical development is NCX 470, a novel nitric oxide-donating prostaglandin analog for the reduction of intraocular pressure in patients with glaucoma or ocular hypertension. It is also conducting research on NCX 1728, a NO-donating phosphodiesterase 5 inhibitor, in retinal diseases. NCX 4251, a patented ophthalmic suspension of fluticasone propionate nanocrystals, for topical ocular application for dry eye, is being developed by Ocumension Therapeutics in China. Nicox generates revenue from VYZULTA in glaucoma and ZERVIATE in allergic conjunctivitis.

Nicox (XPAR:ALCOX) Headlines

No Headlines